Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience. Issue 21 (8th September 2017)

• Record Type: Journal Article
• Authors: Blum Murphy, Mariela; Xiao, Lianchum; Patel, Viren R.; Maru, Dipen M.; Correa, Arlene M.; G. Amlashi, Fatemeh; Liao, Zhongxing; Komaki, Ritsuko; Lin, Steven H.; Skinner, Heath D.; Vaporciyan, Ara; Walsh, Garrett L.; Swisher, Stephen G.; Sepesi, Boris; Lee, Jeffrey H.; Bhutani, Manoop S.; Weston, Brian; Hofstetter, Wayne L.; Ajani, Jaffer A.
• Is Part Of: Cancer. Volume 123:Issue 21(2017)
• Page Start: 4106
• Page End: 4113
• Publication Date: 2017-09-08
• Subjects: esophageal cancer -- neoadjuvant -- pathological complete response -- remission -- survival; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.30953
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Reports are limited regarding clinical and pretreatment features that might predict a pathological complete response (pathCR) after treatment in patients with esophageal cancer (EC). This might allow patient selection for different strategies. This study examines the association of a pathCR with pretreatment variables, overall survival (OS), recurrence‐free survival (RFS), and patterns of recurrence in a large cohort from a single institution. METHODS: The baseline clinical features of 911 consecutive patients with EC who were treated with trimodality therapy from January 2000 to November 2013 were analyzed. A pathCR was defined as a surgical specimen with no residual carcinoma (primary or nodes). Logistic regressions were used to identify independent baseline features associated with a pathCR. We applied log‐rank testing and Cox models to determine the association between a pathCR and the time‐to‐event outcomes (OS and RFS). RESULTS: Of 911 patients, 218 (23.9%) achieved a pathCR. The pathCR rate was 23.1% for adenocarcinoma and 32.2% for squamous cell carcinoma. A lower pathCR rate was observed for 1) older patients (>60 years), 2) patients with poorly differentiated tumors, 3) patients with signet ring cells (SRCs), and 4) patients with a higher T stage. Patients with a pathCR had longer OS and RFS than those without a pathCR ( P = .0021 and P = .0011, respectively). Recurrences occurred more in non‐pathCR patients. Distant metastases were the most common type of recurrence. PathCR patients developed brain metastases at a marginally higher rate than non‐pathCR patients ( P = .051). CONCLUSIONS: In this large cohort study, a pathCR is confirmed to be associated with better OS and RFS. The presence of a poorly differentiated tumor or SRCs reduces the likelihood of a pathCR. Future research should focus on molecular classifiers. Cancer 2017;123:4106–4113. © 2017 American Cancer Society . Abstract : A pathological complete response is associated with better overall survival and recurrence‐free survival. A higher T stage and the presence of poorly differentiated tumors or signet ring cells reduce the likelihood of a pathological complete response. See also pages 4097‐8.